A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Combined Modality Therapy
Antineoplastic Combined Chemotherapy Protocols
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Bone Marrow Transplantation
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Hematopoietic Stem Cell Transplantation
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Drug Administration Schedule
A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
Lupus Erythematosus, Discoid
A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur.
Electronic volume analysis of L1210 chemotherapy. (1/816)The rapid analysis of in vivo chemotherapy on the L1210 ascites tumor grown in C57BL/6 X DBA/2F1 mice has been shown by means of an electronic volume analysis. The drugs were injected on the 4th day of tumor growth, and the cells in the peritoneal cavity were studied at 24-hr intervals on the 5th through 7th day. Using the electronic cell volume distributions, combined with labeling indices, cell morphology, and cell counts, it was found that the alkylating agents. 1,3-bis(2-chloroethyl)-1-nitrosourea and cyclophosphamide, at the dosages used, were more effective than the S-phase-specific drugs, palmitoyl ester of 1-beta-D-arabinofuranosylcytosine, vincristine, and methotrexate. (+info)
The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (2/816)We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients. (+info)
Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. (3/816)PURPOSE: The primary objective of this clinical study was to assess the feasibility of administering recombinant interleukin-2 and recombinant interferon alfa-2a before and after combination cytotoxic chemotherapy. After encouraging initial responses, the study was expanded to further evaluate the therapeutic potential, clarify the toxicities of this regimen, and explore any associated immunologic changes. PATIENTS AND METHODS: Eighty-four patients with metastatic melanoma, including patients with brain metastases, were treated on this 6-week protocol. Patients received combination cisplatin (25 mg/m2/d) and dacarbazine (220 mg/m2/d) on days 1 through 3 and 22 through 24 plus carmustine (150 mg/m2) on day 1. Interleukin 2 (13.5 million IU/m2/d) and interferon alfa (6 MU/m2/d) were administered on days 4 through 8 and 17 through 21. RESULTS: Among 83 patients assessable for response, 12 complete and 34 partial responses were documented (55% response rate). The median time to disease progression was 7 months, the median survival from study entry was 12.2 months, and the median survival from diagnosis of metastatic disease was 15.5 months. Although patients were hospitalized to receive treatment, intensive care unit support generally was not needed. Dose-limiting toxicities were related to elevations in serum bilirubin and serum creatinine levels. No patient developed a grade 4 clinical toxicity. Treatment produced a skin depigmentation, which was associated with prolonged survival. CONCLUSION: A plateau in both the survival and time to progression curves beyond 2 years (15% of the patients) and a greater than 10% disease-free survival beyond 4 years indicate that there may be a long-term benefit for some patients. The limited toxicity of this regimen should permit its use in most oncology settings. A randomized trial of chemoimmunotherapy versus chemotherapy should be performed to establish the value of chemoimmunotherapy for melanoma. (+info)
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. (4/816)Transplantation after high-dose chemotherapy prolongs survival in patients with multiple myeloma compared with standard therapy. It is unclear whether the optimal timing of transplantation is immediately after induction chemotherapy or whether stem cells may be cryopreserved for transplantation at subsequent progression or relapse. In this study, stem cells were collected within 6 months of diagnosis, followed by transplantation only at progression of myeloma. One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved. Eleven had transplants early in the disease after they demonstrated failure to respond to primary therapy. The remaining 107 were eligible for transplants when there was evidence of progressive disease. Of the 118 patients, 67 had transplants, nine died of progressive disease before transplantation, and 42 remain alive in plateau phase. The median survival of the group is 58.5 months; 67 are alive. Serum beta2-microglobulin, bone marrow labeling index (S phase), and hemoglobin level predicted overall survival (P < 0.006, P < 0.001, and P < 0.01, respectively). We conclude that early cryopreservation of blood stem cells followed by transplantation at progression is a feasible approach to therapy in patients with myeloma. The underlying biology of the disease has a greater impact on survival than the timing of transplantation. A prospective randomized trial is required to answer definitively the question of the optimal timing of blood cell transplantation. (+info)
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. (5/816)A patient with a stage IV mantle cell lymphoma (according to the REAL classification) was treated with high-dose chemotherapy and autologous bone marrow transplantation. One year later while on alpha-interferon immunotherapy she suffered from progressive loss of short-term memory and reported difficulties in recognizing objects. Magnetic resonance imaging (MRI) showed a vast ring-enhancing lesion of the left postcentral parietal area. Serial stereotactic biopsies disclosed progressive multifocal leukoencephalopathy without JC-virus in the cerebrospinal fluid. Therapy with subcutaneous interleukin-2 (IL-2) every other day and intrathecal cytarabine once a week was started. After 4 weeks the patient refused further treatment. Nevertheless her condition improved over the next 8 months and MRI scans showed a marked improvement in the lesions. (+info)
Role of antioxidant defenses against ethanol-induced damage in cultured rat gastric epithelial cells. (6/816)Reactive oxygen species appears to be involved in the pathogenesis of ethanol-induced gastric mucosal injury in vivo. Because ingested ethanol diffuses into the gastric mucosa, targeting both epithelium and endothelium, in the present study we examined the possible protective effect of antioxidants on ethanol damage in gastric epithelial cells and endothelial cells in vitro. Cytotoxicity by ethanol was quantified by measuring 51Cr release. The effects of impairment of the glutathione redox cycle and of inhibition of cellular catalase were examined. The generation of superoxide was assessed by the reduction in cytochrome c. Ethanol caused a time- and dose-dependent increase in 51Cr release from epithelial cells. Incubation of cells with DL-buthionine-(S,R)-sulfoximine, while reducing glutathione production, dose dependently enhanced ethanol-induced injury. 1,3-Bis(chloroethyl)-nitrosourea, while inhibiting glutathione reductase activity, also sensitized cells to ethanol. In contrast, the inhibition of catalase with 3-amino-1,2, 4-triazole did not alter the susceptibility of epithelial cells to ethanol. Ethanol induced damage to endothelial cells in a similar fashion. In endothelial cells, however, neither impairment of the glutathione cycle nor inhibition of catalase influenced ethanol-induced damage. Epithelial cells, when exposed to ethanol, increased superoxide production as a function of ethanol concentration, whereas endothelial cells did not. The glutathione redox cycle, but not cellular catalase, plays a critical role in protecting epithelial cells against ethanol damage, whereas neither antioxidant seems to play a role in protection of endothelial cells. The distinct difference in antioxidant protection against ethanol appears to depend on the capability of each cell to produce cytotoxic oxygen species in response to ethanol exposure. (+info)
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. (7/816)The purpose of this study was to describe acute encephalopathy as a new toxicity associated with paclitaxel, when it is delivered at high doses (> or =600 mg/m2) with stem cell support. A total of 129 patients, included in clinical trials of paclitaxel-containing high-dose chemotherapy, were analyzed. A total of 114 patients received paclitaxel at a dose of > or =600 mg/m2. Six patients presented acute encephalopathy starting between 7 and 23 days after paclitaxel treatment; two of them had received prior whole-brain irradiation. Paclitaxel was given alone (one patient), with cyclophosphamide and cisplatin (two patients), and with cyclophosphamide and cisplatin plus 1,3-bis(2-chloroethyl)-1-nitrosourea (three patients). Central nervous system toxicity consisted of rapid obtundation and coma (five patients) and severe confusional picture with paranoid ideations (one patient). Brain magnetic resonance imaging showed diffuse white matter atrophy (one patient) or multiple small infarcts (one patient), or it was normal (four patients). Other complementary tests, including cerebrospinal fluid analysis and electroencephalography, were nondiagnostic. An effect from concomitant psychotropic medications or from other organ toxicities was excluded in all patients. Three patients recovered after 8-15 days, either spontaneously (two patients) or after high-dose steroids (one patient). Three patients died of irreversible coma. Necropsy, performed in two patients, showed generalized white matter atrophy and multiple brain parenchymal infarcts, respectively. No pharmacodynamic correlation between the occurrence of encephalopathy and a pharmacokinetic parameter of paclitaxel could be identified. Paclitaxel-containing high-dose chemotherapy can cause severe acute encephalopathy. An aggravating effect from prior brain irradiation or concurrent 1,3-bis(2-chloroethyl)-1-nitrosourea seems possible. (+info)
Influence of O6-benzylguanine on the anti-tumour activity and normal tissue toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea and molecular combinations of 5-fluorouracil and 2-chloroethyl-1-nitrosourea in mice. (8/816)Previous studies have demonstrated that novel molecular combinations of 5-fluorouracil (5FU) and 2-chloroethyl-1-nitrosourea (CNU) have good preclinical activity and may exert less myelotoxicity than the clinically used nitrosoureas such as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). This study examined the effect of O6-alkylguanine-DNA-alkyltransferase (ATase) depletion by the pseudosubstrate O6-benzylguanine (BG) on the anti-tumour activity and normal tissue toxicity in mice of three such molecular combinations, in comparison with BCNU. When used as single agents at their maximum tolerated dose, all three novel compounds produced a significant growth retardation of BCNU-resistant murine colon and human breast xenografts. This in vivo anti-tumour effect was potentiated by BG, but was accompanied by severe myelotoxicity as judged by spleen colony forming assays. However, while tumour resistance to BCNU was overcome using BG, this was at the expense of enhanced bone marrow, gut and liver toxicity. Therefore, although this ATase-depletion approach resulted in improved anti-tumour activity for all three 5-FU:CNU molecular combinations, the potentiated toxicities in already dose-limiting tissues indicate that these types of agents offer no therapeutic advantage over BCNU when they are used together with BG. (+info)
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors - Full Text View - ClinicalTrials.gov
OBJECTIVES:. I. Determine the maximum tolerated dose and the dose limiting toxicity of carmustine administered after O6-benzylguanine in children with refractory primary CNS tumors.. II. Determine a safe and tolerable dose of carmustine administered after O6-benzylguanine to be used in phase II studies.. III. Determine the pharmacokinetics of O6-benzylguanine and its metabolite, O6-benzyl-8-oxoguanine, in these patients.. IV. Seek preliminary evidence of antitumor activity of this regimen in these patients.. V. Evaluate the acute and chronic toxicities, and describe cumulative toxicity, in patients treated with multiple courses of this regimen.. OUTLINE: This is a dose escalation study of carmustine.. Patients receive O6-benzylguanine IV over 1 hour, then, 1 hour later, carmustine IV is administered over 1 hour. Treatment is repeated every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each receive escalating doses of carmustine ...
WSAVA 2001 - CARMUSTINE ASSOCIATED TO VINCRISTINE AND PREDNISONE IN THE TREATMENT OF CANINE LYMPHOMA
CARMUSTINE ASSOCIATED TO VINCRISTINE AND PREDNISONE IN THE TREATMENT OF CANINE LYMPHOMA. LUCAS, S.R.R.1; COELHO, B.M.P1; MARQUEZI, M.L.; FRANCHINI, M.L.; POZZI, D.H.B2. A chemotherapeutic protocol using carmustine-BCNU (50mg/m2 at 6 weeks intervals) associated with vincristine (0,75mg/m2 at 3 weeks intervals) and prednisone (40 mg/m2 each other day) was evaluated in dogs with malignant lymphoma. Carmustine is a highly lipid-soluble chemotherapeutic agent in the nitrosourea subclass that rapidly crosses the blood-brain barrier and acts as a nonphase-specific alkylant agent. Seven dogs with multicentric lymphoma, stage III to V according WHO, were admitted and treated at the Veterinary Medical Teaching Hospital of the University of S o Paulo, Brazil. The dogs received 2 to 7 cycles chemotherapics with carmustine plus VCR (median 5) and 4 to 8 cycles (median 6) only with VCR. Cumulatives doses of carmustine ranged from 100 to 298 mg/m2. Six dogs (85,7%), achieved complete remission after induction ...
NDC 68475-503 Carmustine Carmustine
Carmustine with NDC 68475-503 is a a human prescription drug product labeled by Navinta Llc. The generic name of Carmustine is carmustine.
Recent evidence from our laboratory and from others suggested that pretreatment with α-difluoromethylornithine (DFMO) sensitizes some human and rodent tumor cell lines to l,3-bis(2-chloroethyl)-l-nitrosourea (BCNU). Many human tumor cells are resistant to chloroethylnitrosourea-induced DNA interstrand cross-linking and cell kill due to their high levels of the DNA repair protein O6-alkylguanine DNA alkyltransferase. We therefore investigated DFMO-mediated sensitization to BCNU in BCNU-sensitive and -resistant cells. Colony formation assays were used to compare BCNU cytotoxicity in DFMO-pretreated and control cultures of two colon tumor lines, HT-29 cells, which have high alkyltransferase levels and thus are BCNU-resistant, and BE cells, which are deficient in this repair capacity and thus are BCNU-sensitive. Polyamine depletion significantly enhanced BCNU cytotoxicity only for the repair-proficient HT-29 cell line. BE cells were 40-fold more sensitive to BCNU than were HT-29 cultures. However, ...
Definition of carmustine implant - NCI Drug Dictionary - National Cancer Institute
A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.
DailyMed - BICNU - carmustine
Risk Summary BiCNU (carmustine for injection) can cause fetal harm when administered to a pregnant woman based on the mechanism of action [see Clinical Pharmacology (12.1)] and findings in animals [see Data]. Limited available data with BiCNU use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage. Carmustine was embryotoxic in rats and rabbits and teratogenic in rats (thoracoabdominal closure, neural tube, and eye defects and malformations of the skeletal system of the fetus) when given in doses lower than the maximum cumulative human dose based on body surface area. Consider the benefits and risks of BiCNU for the mother and possible risks to the fetus when prescribing BiCNU to a pregnant woman. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the ...
Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy | Molecular Cytogenetics | Full Text
To assess the influence of molecular markers with potential prognostic value to groups of patients with newly diagnosed glioblastoma patients were examined: group A with 36 patients (surgical resection plus standard combined chemoradiotherapy) and group B with 36 patients (surgical resection, standard combined chemoradiotherapy plus carmustine wafer implantation). Our aim was to determine chromosomal alterations, methylation status of MGMT, p15, and p16 (CDKN2A) in order to analyse the influence on patient survival time as well as radio- and chemotherapy responses. Promoter hypermethylation of MGMT, p16, and p15 genes were determined by MS-PCR. Comparative genomic hybridisation (CGH) analyses were performed with isolated, labelled DNA of each tumor to detect genetic alterations. Age of onset of the disease showed a significant effect on overall survival (OS) (p < 0.0001). Additional treatment with carmustine wafer (group B) compared to the control group (group A) did not result in improved OS (p = 0.562
Carmustine in Treating Patients With Recurrent Malignant Glioma - Full Text View - ClinicalTrials.gov
OUTLINE: This is a dose escalation study.. All patients undergo maximal tumor resection. At the time of surgery, groups of 6 patients receive up to 8 polifeprosan 20 wafers containing increasing doses of carmustine implanted into the resection cavity.. Patients with an intraoperative diagnosis other than glioblastoma multiforme or anaplastic astrocytoma do not receive wafer implantation, and are removed from study.. Patients are followed 3, 6, and 12 months after implantation.. PROJECTED ACCRUAL: A total of 52 patients will be accrued for this study. ...
Carmustine (BCNU) Synthesis, SAR, MCQ,Chemical Structure and Therapeutic Uses - Gpatindia: Pharmacy Jobs, Admissions,...
This Info Includes Carmustine structure, SAR, method of synthesis, mechanism of action, therapeutic uses, side effects and multiple choice questions for the preparation for GPAT and Competitive Pharmacy examinations
Carmustine Injection: Indications, Side Effects, Warnings - Drugs.com
Easy-to-read patient leaflet for Carmustine Injection. Includes indications, proper use, special instructions, precautions, and possible side effects.
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch - PharmiWeb.com
Amneal Announces Approval of Carmustine for Injection USP, 100 mg/vial - Preparing for Launch PR Newswire BRIDGEWATER, N.J., Oct. 19, 2018 BRIDGEWATER, N.J., Oct. 19, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc.(NYSE: AMRX), today announced that it has received FDA app...
Our previous in vitro studies demonstrated that SarCNU was more effective than BCNU against human gliomas (Panasci et al., 1985;Skalski et al., 1988). Using transport studies with radiolabeled SarCNU we have demonstrated that the uptake of SarCNU in SKMG-1 cells was more rapid and there was a greater accumulation of SarCNU in SKMG-1 cells compared with SKI-1 cells. This corresponded to the cytotoxicity results, i.e., SKMG-1 cells were more sensitive to SarCNU (Noë et al., 1994, 1996). Using RT-PCR we have confirmed that SKI-1 cells expressed EMTh much less than SKMG-1 cells (Chen et al., 1999b), supporting that the differential cytotoxicity to SarCNU in these cell lines is due to the presence of the EMTh in SKMG-1 cells.. In the present in vivo study, we did not find a correlation between SarCNU antitumor effect and EMTh expression alone, but instead a significant correlation was found with EMTh expression and MGMT expression together. The absence of a linear correlation between SarCNU ...
Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. - PubMed - NCBI
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
S-((2-chloroethyl)carbamoyl)glutathione Summary Report | CureHunter
S-((2-chloroethyl)carbamoyl)glutathione: structure given in first source; product of reaction between glutathione and the anticancer agent 1,3-bis(2-chloroethyl)-N-nitrosourea (BCNU)
After feeling well enough to go for an early morning run yesterday, I was given 6 hours of chemo--Etoposide and Carmustine. Pretty much immediately I felt nauseous, no appetite, hot flashes, dizziness, and I also got the added bonus of a bright red rash caused by the carmustine. I had a few hours off of…
DMOZ - Health: Pharmacy: Drugs and Medications: C: Carmustine
Provides information on usage, precautions, side effects and brand names when available. Data provided by various government agencies and health-related organizations. ...
Search results | NICE
NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the ...
ChemIDplus - 52320-87-3 - MLZCGCGQWWRMMX-UHFFFAOYSA-N - Alanine, N-(((2-chloroethyl)nitrosoamino)carbonyl)-2-methyl- - Similar...
52320-87-3 - MLZCGCGQWWRMMX-UHFFFAOYSA-N - Alanine, N-(((2-chloroethyl)nitrosoamino)carbonyl)-2-methyl- - Similar structures search, synonyms, formulas, resource links, and other chemical information.
PQR | N,n-bis(2-chloroethyl)-1,4-benzenediamine
You are viewing an interactive 3D depiction of the molecule n,n-bis(2-chloroethyl)-1,4-benzenediamine (C10H14Cl2N2) from the PQR.
REFLEX ELEXOVÁ, Košice - Tel.: +421556337... >> Papiernictvá | Zlaté...
Kotaktujte nás. REFLEX ELEXOVÁ, Košice. Hodnotenia: ... dobré ceny, príjemný a ústretový personál. Nakupujem u nich pravidelne. Jednoznačne...
Glioblastoma fed by middle meningeal artery and displaying cyst formation soon after repeated implantation of carmustine wafers...
The extent of resection by surgery affects survival time in GBM patients (5,6). A better prognosis might therefor be predicted for right temporal lobe localized GBM, since total removal can be carried out.. The present case was initially diagnosed as meningioma, because the tumor stain was clearly seen from the middle meningeal artery but not from the internal carotid artery. Only a few case reports of such GBMs have been described (7,8). The timing of surgical treatment may easily be delayed if the lesion is misdiagnosed as a meningioma, and may be of concern for the prognosis of GBM patients.. Cyst formation is known to occur as an adverse event of carmustine wafer implantation for malignant gliomas (9), and there have been several reports of space-occupying cysts in the cavity, which required additional surgical treatment (10-13). Yoshida et al reported that adverse events associated with implantation of carmustine wafers tend to occur in the repeated surgery for the malignant gliomas (11). ...
Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits...
TY - JOUR. T1 - Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth. AU - Weydert, Christine J.. AU - Zhang, Yuping. AU - Sun, Wenqing. AU - Waugh, Trent A.. AU - Teoh, Melissa L.T.. AU - Andringa, Kelly K.. AU - Aykin-Burns, Nukhet. AU - Spitz, Douglas R.. AU - Smith, Brian J.. AU - Oberley, Larry W.. N1 - Funding Information: This research was supported by grants from the National Institute of Health, P01 CA66081 and T32 CA78586, and the Holden Comprehensive Cancer Center at the University of Iowa. We thank the following for their generous contributions to our project: Viraquest, Inc., personnel in the Office of Animal Resources at the University of Iowa, Dr. Sujatha Venkataraman, and Susan Walsh.. PY - 2008/3/1. Y1 - 2008/3/1. N2 - Superoxide dismutases (SODs) have been found to decrease tumor formation and angiogenesis. SOD gene therapy, as with many other gene transfer strategies, may not ...
Nitrosourea-induced pulmonary injury
The nitrosourea drugs, a class of DNA alkylating agents related to nitrogen mustards, include(BCNU),(CCNU), semustine (methyl CCNU), and chloroethylnitrosourea (Sar-CNU). Nitrosourea drugs are used to treat lymphoma, brain tumors, melanoma, and other
The Treatment of One or Two Supratentorial Brain Metastases With Surgical Resection and BCNU-Polymer Wafers [carmustine...
Restricted Access Oops, it looks like you dont have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following. ...
Effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds by H E. Kann, K W. Kohn et al.
Kann, H E.; Kohn, K W.; Widerlite, L; and Gullion, D, Effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds on nuclear rna metabolism. (1974). Subject Strain Bibliography 1974. 1674 ...
CAS No.5081-87-8,2,4(1H,3H)-Quinazolinedione,3-(2-chloroethyl)- Suppliers,MSDS download
Find quality suppliers and manufacturers of 5081-87-8(2,4(1H,3H)-Quinazolinedione,3-(2-chloroethyl)-) for price inquiry. where to buy 5081-87-8(2,4(1H,3H)-Quinazolinedione,3-(2-chloroethyl)-).Also offer free database of 5081-87-8(2,4(1H,3H)-Quinazolinedione,3-(2-chloroethyl)-) including MSDS sheet(poisoning, toxicity, hazards and safety),chemical properties,Formula, density and structure, solution etc.
Your Mind & Cancer Treatment: The Latest Research on Chemotherapy-related Cognitive Decline - Pine Street Foundation
In the November 2006 issue of the Journal of Biology, researchers report that chemotherapy drugs - specifically carmustine, cisplatin, and cytosine arabinoside - were associated with increased cell damage and death in the brains of mice; this effect was seen for weeks after the drugs were administered.2. Researchers also found that neural progenitor cells (sometimes called neural stem cells since they have the ability to restore function in damaged nerve tissues) and oligodendrocytes (a type of cell found in the brain and spinal cord that helps improve the speed and reliability of impulse conductions, allowing faster information processing and better motor control) are exceptionally vulnerable to the action of chemotherapeutic drugs; this is the first study to show definitive evidence of chemotherapys damaging effects on the physical structure of the brain.. What is particularly interesting about this study is that this damage was found both in vitro (cells cultured or tested in the ...
N-(2-Chloro-1,1-ditritioethyl)-N-(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine | C7H15Cl2N2O2P - PubChem
N-(2-Chloro-1,1-ditritioethyl)-N-(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine | C7H15Cl2N2O2P | CID 57817016 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
2-chloroethyl 4-nitrophenyl propyl phosphate | C11H15ClNO6P - PubChem
2-chloroethyl 4-nitrophenyl propyl phosphate | C11H15ClNO6P | CID 120363 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
Boronic acid,B-[3-[[(2-chloroethyl)amino]carbonyl]phenyl]- - Alfa Chemistry
Boronic acid,B-[3-[[(2-chloroethyl)amino]carbonyl]phenyl]-/ACM874288127 can be provided in Alfa Chemistry. We are dedicated to provide our customers the best products and services.
CAS # 120-88-7, N,N-Bis(dodecyl)dithiooxamide, N,N-Didodecylethanedithioamide, NSC 44699
chemBlink provides information about CAS # 120-88-7, N,N-Bis(dodecyl)dithiooxamide, N,N-Didodecylethanedithioamide, NSC 44699, molecular formula: C26H52N2S2.
Method of inspecting bonded wafers - Shin-Etsu Handotai Co., Ltd.
A method of inspecting bonded wafers, which involves obtaining a Lang topograph of bonded wafers as a sample by using a Lang camera, or further treating an image thereon, thereby detecting unbonded re
Are klonopin wafers faster acting than klonopin pills?
2 Answers - Posted in: ativan, klonopin, klonopin wafer, xanax, depression - Answer: Without looking it up, I suspect wafers enter the blood stream ...
Role of O6-alkylguanine-DNA alkyltransferase in the resistance of mouse spermatogenic cells to O6-alkylating agents.
The O(6)-alkylguanine-DNA alkyltransferase inactivator O(6)-benzylguanine was administered to BALB/c mice either alone or before exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea to study the role of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase in the protection of the testis against anti-cancer O(6)-alkylating agents. Exposure of the mice to 1, 3-bis(2-chloroethyl)-1-nitrosourea or O(6)-benzylguanine alone did not produce any marked testicular toxicity at the times studied. Testicular O(6)-alkylguanine-DNA alkyltransferase concentrations were assayed between 0 and 240 min after O(6)-benzylguanine treatment and were shown to be , 95% depleted 15 min after treatment with O(6)-benzylguanine and remained at , 95% at all the times assayed. Histological examination, the reduction in testicular mass and the induction of spermatogenic cell apoptosis showed that this depletion significantly potentiated 1, 3-bis(2-chloroethyl)-1-nitrosourea-induced testicular damage after treatment. Major ...
Carmustine Lomustine and Semustine - Pharmacology
The nitrosoureas are alkylating agents that are highly lipid soluble and share similar pharmacological and clinical properties. Carmustine (BCNU), lomustine
Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131...
PURPOSE This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS Patients with chemotherapy-sensitive persistent or relapsed DLBCL were randomly assigned to receive iodine-131 tositumomab (dosimetric dose of 5 mCi on day -19 and therapeutic dose of 0.75 Gy on day -12), carmustine 300 mg/m2 (day -6), etoposide 100 mg/m2 twice daily (days -5 to -2), cytarabine 100 mg/m2 twice daily (days -5 to -2), and melphalan 140 mg/m2 (day -1; B-BEAM) or rituximab 375 mg/m2 on days -19 and -12 and the same chemotherapy regimen (R-BEAM).ResultsTwo hundred twenty-four patients were enrolled, with 113 patients randomly assigned to R-BEAM and 111 patients assigned to B-BEAM. Two-year progression-free survival (PFS) rates, the primary end point, were 48.6% (95% CI, 38.6% to 57.8%) ...
Chemotherapy and bio-chemotherapy in patients with advanced melanoma: Combination therapy with a nitrosourea<...
TY - JOUR. T1 - Chemotherapy and bio-chemotherapy in patients with advanced melanoma. T2 - Combination therapy with a nitrosourea. AU - Ridolfi, Ruggero. AU - Tanganelli, L.. AU - Scelzi, E.. AU - Manente, P.. AU - Palmeri, S.. AU - Ravaioli, A.. AU - Fiammenghi, L.. AU - Romanini, A.. PY - 2003/4. Y1 - 2003/4. N2 - The treatment of advanced melanoma is still disappointing. In a multicenter randomized clinical trial to compare a chemotherapy (CT) with or without low doses of IL-2 and IFN (Bio-CT), the participating centers chose whether or not to add a nitrosourea, carmustine (BCNU) to the therapy. The aim of the present paper is to report the clinical results of the patients (pts) treated in both arms with BCNU. One hundred and seventy-six pts with advanced melanoma were enrolled in the study from 27 centers and a total of 18 pts also received BCNU in 3 centers. No further changes to the protocol criteria were allowed. One patient refused the treatment. No complete responses were observed. ...
O6-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea in four...
The protein O6-alkylguanine-DNA alkyltransferase (O6-AGT) has been implicated as a major determinant of resistance of diverse tumors to chloroethylnitrosoureas. To evaluate the contribution of O6-AGT to resistance of medulloblastomas to chloroethylnitrosoureas, we assessed the role of O6-AGT in dete …
Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model<...
TY - JOUR. T1 - Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model. AU - Guarnieri, Michael. AU - Biser-Rohrbaugh, Ann. AU - Tyler, Betty Mae. AU - Gabikian, Patrik. AU - Bunton, Tracie E.. AU - Ze Wu, Qing. AU - Weingart, Jon David. AU - Solomon, Benjamin. PY - 2002. Y1 - 2002. N2 - Purpose: The DNA-repair protein, O6-alkylguanine-DNA alkyl transferase, may account for resistance of CNS tumors to DNA-alkylating drugs, such as bis-(2-chloroethyl)-1-nitrosourea (BCNU). The therapeutic effects of BCNU can be potentiated by inhibiting the repair protein with an alkylated guanine analog, O6-benzyl guanine (O6BG). To investigate potential toxicity of this inhibition, we examined the effects of O6BG in mice treated with intracranial (i.c.) BCNU given via a biodegradable polymer. Methods: Mice were treated with escalating doses of BCNU chronically delivered i.c., and with chronically delivered O6BG. The O6BG was delivered via a ...
Guilford Pharmaceuticals Receives European Marketing Authorization for Expanded Use of GLIADEL(R) Wafer - GLIADEL(R) Approved...
Brain tumor news: Guilford Pharmaceuticals Receives European Marketing Authorization for Expanded Use of GLIADEL(R) Wafer - GLIADEL(R) Approved to Treat Newly-Diagnosed Patients with Malignant Glioma
BCNU | definition of BCNU by Medical dictionary
Looking for online definition of BCNU in the Medical Dictionary? BCNU explanation free. What is BCNU? Meaning of BCNU medical term. What does BCNU mean?
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
The purpose of the PRECISE trial is to determine whether overall survival duration, safety, and quality of life are improved for patients treated with I
Bulk Manufacturer & Supplier of Acetic Acid 2-Chloroethyl Ester CAS:542-58-5 | Brenlabs.com
We manufacture Acetic Acid 2-Chloroethyl Ester CAS:542-58-5 from China India,Ethanol, 2-chloro-, acetate factory and Acetic Acid 2-Chloroethyl Ester producer,Acetic Acid 2-Chloroethyl Ester manufacturer and supplier
1grh.1 | SWISS-MODEL Template Library
SWISS-MODEL Template Library (SMTL) entry for 1grh.1. INHIBITION OF HUMAN GLUTATHIONE REDUCTASE BY THE NITROSOUREA DRUGS 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA AND 1-(2-CHLOROETHYL)-3-(2-HYDROXYETHYL)-1-NITROSOUREA
Gliadel is really thought to be the first decision for gliadel
Can Gliadel raise my blood sugar at levels and cause bladder are pain. Specifically, never take effective chew product and Panobinostat biloba, a known interaction sites with serious health insurance risks. We both want to demonstrate fewer episodes of diarrhea and fewer post operatory cardiovascular and subsequent neurologic events in the groups receiving prophylactic Kao -
Leucine, N-(N-acetyl-3-(p-(bis(2-chloroethyl)amino)phenyl)-DL-alanyl)- , ethyl ester, L- (CAS 3577-89-7) Market Research...
The report generally describes leucine, n-(n-acetyl-3-(p-(bis(2-chloroethyl)amino)phenyl)-dl-alanyl)- , ethyl ester, l-, examines its uses, production
PQR | N-[(2-chloroethyl)(nitroso)carbamoyl]-l-alanyl-l-alanine
You are viewing an interactive 3D depiction of the molecule n-[(2-chloroethyl)(nitroso)carbamoyl]-l-alanyl-l-alanine (C9H15ClN4O5) from the PQR.
ChemIDplus - 149194-25-2 - ZMDLBLZFZSHVLH-UHFFFAOYSA-N - 1-Acetyl-1,2-bis(methylsulfonyl)-2-(2-chloroethyl)hydrazine - Similar...
149194-25-2 - ZMDLBLZFZSHVLH-UHFFFAOYSA-N - 1-Acetyl-1,2-bis(methylsulfonyl)-2-(2-chloroethyl)hydrazine - Similar structures search, synonyms, formulas, resource links, and other chemical information.
US5213451A - Apparatus and method of automatically separating stacked wafers - Google Patents
The separation of thin disk-type workpieces from a stack has, as a rule, hitherto been carried out by hand. An apparatus and a corresponding method are now provided which make it possible to lift the wafer off the stack without mechanical contact, and also to convey the separated wafers to the tray and to introduce them in an automated way without damage. In this method, a stack of disk-type workpieces is introduced into a wafer magazine with a feed unit which brings the uppermost wafer of the wafer stack into the sphere of action of a fluid medium which emerges under pressure in a preferred direction from a nozzle system. A dam makes it possible to remove a single wafer. The apparatus and the method make possible separation without damage while increasing the yield. In conjunction with a conveying apparatus, an apparatus for tray filling processing lines can be built up for automatically treating disk-type workpieces without damage.
Kedy chodíte spať? - Život - BIRDZ.SK
keď chodím do školy alebo niekde ráno, tak sa snažím medzi 23:00 až 00:00 a keď nie, tak medzi 00:00 až 1:00 ale väčšinou keď mam na ďalší deň skúšku a musím sa učiť a nestíham tak potiahnem aj do druhej a vstávam o piatej káva a ideme sa učiť :D ...
update on new wafers - Ostomies - HealingWell.com Forum
It took a couple weeks but I wanted to wait and see how well the new wafers worked. After a few changings, Im happy to announce that I got some relief and now its staying on for 4 days!!!!!!!!! YYAAYYYY !!! I wouldve loved 5 or more days but whos complaining..haha ...
"Carmustine". Drug Information Portal. U.S. National Library of Medicine. "Carmustine Implant". MedlinePlus. Portal: Medicine ( ... "Bicnu- carmustine kit". DailyMed. Retrieved 27 February 2021. "Gliadel- carmustine wafer". DailyMed. Retrieved 27 February 2021 ... Carmustine, sold under the brand name BiCNU among others, is a medication used mainly for chemotherapy. It is a nitrogen ... Carmustine for injection was marketed under the name BiCNU by Bristol-Myers Squibb and now[when?] by Emcure Pharmaceuticals. In ...
... has a long time to nadir (the time when white blood cells reach their lowest number). Unlike carmustine, lomustine is ...
Gliadel Wafer (Carmustine), for cancer, now owned by Arbor Pharmaceuticals. Jevtana (Cabazitaxel), for prostate cancer. Kevzara ...
With this step carmustine (BCNU), another medication used for chemotherapy, is formed. BCNU is subsequently decomposed in the ...
At therapeutic doses, those side effects are usually relatively milder compared with carmustine and lomustine. Pokrovskiĭ VS, ...
... carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease". J. Clin. Oncol. 9 ...
Nitrosoureas include N-Nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU) and semustine (MeCCNU), fotemustine and ...
Other compounds used in cancer chemotherapy that have the ability to form ICLs are cisplatin, mitomycin C, carmustine, and ...
Crosslinking of DNA
Chloro ethyl nitroso urea (CENU), specifically carmustine (BCNU), are crosslinking agents that are widely used in chemotherapy ...
Focused ultrasound for intracranial drug delivery
Another study found encapsulating carmustine in microbubbles led to a five-fold increase in the circulating half-life and a ... This study also found combining these carmustine-loaded microbubbles with FUS increased the median survival time by 12% in a ...
... carmustine) for brain tumors into the Eisai product portfolio. In 2009, Eisai received the Corporate Award from the National ... carmustine) - Treatment for Brain Tumors Lenvima (lenvatinib) - Thyroid Cancer or Kidney Cancer Aricept accounted for 40% of ...
Alkylating antineoplastic agent
Uramustine or uracil mustard Melphalan Chlorambucil Ifosfamide Bendamustine Nitrosoureas Carmustine Lomustine Streptozocin ...
CBV refers to Cytoxan (cyclophosphamide), BCNU (carmustine), and VP-16 (etoposide), three drugs in a chemotherapy regimen ...
Thomas A. Waldmann
"90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous ...
Nanoparticles for drug delivery to the brain
... carmustine, facilitates the safe treatment of glioblastoma in an animal model. This drug, like many others, normally requires ...
Several drugs such as procarbazine, streptozotocin, BCNU (carmustine), and temozolamide are designed to remodel DNA to reverse ...
Limited-stage small cell lung carcinoma
High-dose chemotherapy using cyclophosphamide, cisplatin, and carmustine with hematologic stem-cell support or marrow support ...
Plasma cell leukemia
... carmustine, melphalan, and prednisone alternating with vincristine, carmustine, doxorubicin, and prednisone. The treatment of ...
... carmustine). Also, some medicinal drugs used in cardiovascular medicine can lead to pulmonary toxicity frequently or very ...
ATC code L01
Busulfan L01AB02 Treosulfan L01AB03 Mannosulfan L01AC01 Thiotepa L01AC02 Triaziquone L01AC03 Carboquone L01AD01 Carmustine ...
Chemotherapy-induced nausea and vomiting
ABVD AC BEP Cisplatin Carmustine (>250 mg/m2) CBV Cyclophosphamide (>1500 mg/m2) Dacarbazine Mechlorethamine MOPP/COPP/BEACOPP ...
List of MeSH codes (D02)
... carmustine MeSH D02.654.692.300 - ethylnitrosourea MeSH D02.654.692.440 - lomustine MeSH D02.654.692.440.700 - semustine MeSH ... carmustine MeSH D02.948.594.310 - ethylnitrosourea MeSH D02.948.594.440 - lomustine MeSH D02.948.594.440.700 - semustine MeSH ...
National Cancer Institute
Carmustine) (1977) Cis-diamminedichloroplatinum (Cisplatin) (1978) Mitoxantrone (Novantrone) (1988) Carboplatin (Paraplatin) ( ...
... carmustine, methotrexate, and bleomycin) Hypersensitivity pneumonitis EVALI Radiation pneumonitis Acute interstitial ...
Index of oncology articles
... carmustine - carnitine - carotenoid - carzelesin - case report - case series - case-control study - caspofungin acetate - ... polifeprosan 20 carmustine implant - poly-ICLC - polyglutamate camptothecin - polyglutamate paclitaxel - polymerase chain ...
List of drugs: C-Ca
... carmustine (INN) Carnation Instant Breakfast Carnexiv carnidazole (INN) carnitine (INN) Carnitor carocainide (INN) Caroid ...
Arabinopyranosyl-N-methyl-N-nitrosourea Carmustine Chlorozotocin Ethylnitrosourea Fotemustine Lomustine N-Nitroso-N-methylurea ... Examples include: Arabinopyranosyl-N-methyl-N-nitrosourea (Aranose) Carmustine (BCNU, BiCNU) Chlorozotocin Ethylnitrosourea ( ...
... including carmustine, lomustine, dacarbazine developed by Y Fulmer Shealy, fludarabine, amifostine, clofarabine and the latest ...
Some drugs used in stomach cancer treatment have included: fluorouracil or its analog capecitabine, BCNU (carmustine), methyl- ...
Interstitial lung disease
... carmustine related pulmonary fibrosis, respiratory broncholitis associated with interstitial lung disease. Lower lung ...
Carmustine: MedlinePlus Drug Information
Carmustine: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving carmustine injection,. *tell your doctor and pharmacist if you are allergic to carmustine or any of the ... Carmustine injection is used to treat certain types of brain tumors. Carmustine injection is also used along with prednisone to ... You should not become pregnant while you are receiving carmustine injection. If you become pregnant while receiving carmustine ...
BiCNU, Gliadel (carmustine) dosing, indications, interactions, adverse effects, and more
... carmustine), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, ... carmustine intravenous CARMUSTINE - INJECTION (kar-MUS-teen) COMMON BRAND NAME(S): BiCNU WARNING: Carmustine may cause serious ... encoded search term (carmustine (BiCNU%2C Gliadel)) and carmustine (BiCNU, Gliadel) What to Read Next on Medscape ... You should not become pregnant while using carmustine. Carmustine may harm an unborn baby. Women should ask about reliable ...
Method and Means for Intracranial Implantation of Carmustine Anti-Tumoral Agents
Biodegradable wafers containing the anti-tumoral agent carmustine (BCNU) are often inserted into the surgical void in the brain ... Minimally invasive delivery of carmustine to localized regions of the brain.. • Accurate positioning of the carmustine within ... Biodegradable wafers containing the anti-tumoral agent carmustine (BCNU) are often inserted into the surgical void in the brain ... Method and Means for Intracranial Implantation of Carmustine Anti-Tumoral Agents. ...
Pediatric Non-Hodgkin Lymphoma Medication: Antineoplastics, Other, Antineoplastics, Monoclonal Antibodies, PD-1/PD-L1...
Carmustine - Actiza Pharmaceutical
carmustine Coupons and Discount Cards - rxless
Get your own, free carmustine discount card on rxless.com. ... Save more on your prescription medication with carmustine ... What is carmustine?. CARMUSTINE, BCNU (kar MUS teen) is a chemotherapy drug. It interferes with the growth of rapidly growing ... More ways to save on carmustine. Fill a 90-Day Supply to Save. In some cases, filling your prescription for a 90-day supply ... carmustine Drug Class. Antineoplastic - Alkylating Agent - Nitrosoureas - Drugs that prevent or inhibit the maturation and ...
carmustine | Ligand page | IUPHAR/BPS Guide to IMMUNOPHARMACOLOGY
Possible Interaction: Carmustine and Niacin - SUPP.AI by AI2
Consuim Carmustine Manufacturer, Consuim Carmustine Supplier,Exporter, Tamil Nadu,India
... supplier of Consuim Carmustine and other medicines at low price in Chennai, Tamil Nadu, India. ... Consuim (Carmustine) causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA ... Before starting Consuim (Carmustine) treatment, make sure you tell you doctor about any other medications you are taking ( ... The amount of Consuim (Carmustine) that you will recieve depends on many factors, including your height and weight, your ...
Table 2 - Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness,...
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. ...
Dr Wenbo Zhan | People | The University of Aberdeen
Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells | BMC Cancer | Full Text
Taken together, these data strongly implicate an unexplored role of Nrf2 in glioma resistance to Carmustine and raise the ... In addition, over expression of Nrf2 in U87MG cells significantly attenuated the cytotoxicity of Carmustine as evidenced by ... Consistent with this, antioxidants such as glutathione and N-acetyl cysteine significantly reduced Carmustine mediated glioma ... attenuates glioma cytotoxicity to Carmustine (BCNU), a widely used chemotherapeutic agent known to modulate cellular oxidative ...
Browse by Generic Drug
astrocytoma, anaplastic Clinical Research Trials | CenterWatch
NIOSHTIC-2 Search Results - Full View
Pneumothorax as an Adverse Drug Event: An Exploratory Aggregate Analysis of the US FDA AERS Database Including a Confounding by...
Of note carmustine is the drug with the most established association with pneumothorax based on the occurrence of upper lobe ... Carmustine and docetaxel have the largest and fifth largest EBGM among oncology drugs and were the two oncology drugs ... The CBI analysis (Table 2) is notable for a wide range of UCBIIs with all drug-specific values ,1, and two drugs, carmustine ... Carmustine. 15. 4.75. 8.52. Non-Hodgkins lymphoma. 55. 29.5. 37. 1052/119. 8.84. 4.34. 0.85. ...
Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist | Cell Death &...
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the ... Implants such as carmustine wafers have been tested clinically already and technologies to expand such strategies to biologics ... Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. J Neurooncol. 2015; ...
Calquence (acalabrutinib) dosing, indications, interactions, adverse effects, and more
A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in...
Pediapred (prednisolone sodium phosphate) dose, indications, adverse effects, interactions... from PDR.net
IgM monoclonal gammopathies of clinical significance: diagnosis and management | Haematologica
Navinta Salaries, Average Salary & Jobs Pay
Skin Cancer | Encyclopedia.com
A prospective PET study of patients with glioblastoma multiforme
- Biodegradable wafers containing the anti-tumoral agent carmustine (BCNU) are often inserted into the surgical void in the brain following the debulking of a glioma. (ideaconnection.com)
- CARMUSTINE, BCNU (kar MUS teen) is a chemotherapy drug. (rxless.com)
- In the present study, we hypothesized that the antioxidant transcription factor, Nrf2 (nuclear factor erythroid-derived 2 like 2), attenuates glioma cytotoxicity to Carmustine (BCNU), a widely used chemotherapeutic agent known to modulate cellular oxidative balance. (biomedcentral.com)
- Carmustine or bis-chloroethylnitrosourea (BCNU) wafer is the only FDA approved intracerebral chemotherapeutic agent for the treatment of newly diagnosed and recurrent malignant glioma [ 3 ]. (biomedcentral.com)
- and, Carmustine (BiCNU) - malignant melanoma, brain tumors. (cdc.gov)
- The median survival time of adults with supratentorial malignant glioma treated in clinical studies with surgery, 6 weeks of external-beam radiotherapy, and carmustine (BiCNU) is approximately 1 year. (cancernetwork.com)
- All patients were primarily treated with surgery, followed by chemotherapy (carmustine, cisplatine and etoposide) and radiotherapy. (nih.gov)
- Compare the response rates and time to treatment failure in patients with relapsed or refractory non-Hodgkin's lymphoma treated with iodine I 131 monoclonal antibody anti-B1, followed by high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM), and autologous peripheral blood stem cell transplantation (APBSCT) vs historical control patients treated with high-dose BEAM or carmustine, etoposide, cytarabine, and cyclophosphamide and APBSCT. (knowcancer.com)
- Patients then receive high-dose chemotherapy comprising carmustine IV on day -6, etoposide IV and cytarabine IV twice daily on days -5 to -2, and melphalan IV on day -1. (knowcancer.com)
Delivery of carmustine1
- Minimally invasive delivery of carmustine to localized regions of the brain. (ideaconnection.com)
- After maximal surgical resection of tumors, biodegradable wafers of Carmustine (Gliadel®) are implanted inside the tumor cavity, providing an innovative way of delivering chemotherapy directly to the brain tumors with minimal systemic toxicity and greater efficacy than systemic Carmustine administration [ 4 ]. (biomedcentral.com)
- Carmustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. (humpath.com)
- In 2020, the carmustine market size was around $XX billion. (datavagyanik.com)
- Consuim (Carmustine) causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). (millionpharma.net)
- Other cancers treated with Consuim (Carmustine) include multiple myeloma, Hodgkin's disease, non-Hodgkin's lymphomas, and may be used on the skin (topically) for cutaneous T-cell lymphoma. (millionpharma.net)
- What is the composition of carmustine? (datavagyanik.com)
- Consuim (Carmustine) also binds to and modifies (carbamoylates) glutathione reductase. (millionpharma.net)
- Consistent with this, antioxidants such as glutathione and N-acetyl cysteine significantly reduced Carmustine mediated glioma cytotoxicity. (biomedcentral.com)
- Therefore, by inhibiting glutathione reductase an enzyme that plays critical roles in cellular oxidative balance, Carmustine treatment may modulate the cellular oxidative status. (biomedcentral.com)
- When you get a carmustine discount card for free from rxless, you'll pay the lowest possible price for your medication. (rxless.com)
- Carmustine injection is used to treat certain types of brain tumors. (medlineplus.gov)
- Carmustine injection is also used along with prednisone to treat multiple myeloma (a type of cancer of the bone marrow). (medlineplus.gov)
- Carmustine injection comes as a powder to be added to fluid and injected over at least 2 hours intravenously (into a vein) by a doctor or nurse in a medical office or hospital outpatient clinic. (medlineplus.gov)
- tell your doctor and pharmacist if you are allergic to carmustine or any of the ingredients in carmustine injection. (medlineplus.gov)
- You should not become pregnant while you are receiving carmustine injection. (medlineplus.gov)
- Carmustine injection may cause other side effects. (medlineplus.gov)
- Talk to your doctor about the risk(s) of receiving carmustine injection. (medlineplus.gov)
- Consuim (Carmustine) is usually given by an infusion into a vein (intravenous, IV). (millionpharma.net)
- The lung damage can cause death, especially in patients treated with carmustine as children. (medlineplus.gov)
- Carmustine also can cause lung damage, even years after treatment. (medlineplus.gov)
- To get started, check the section below for other drugs related to carmustine. (rxless.com)
- It is important for you to tell your doctor how you are feeling during your treatment with carmustine. (medlineplus.gov)
- Before starting Consuim (Carmustine) treatment, make sure you tell you doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc. (millionpharma.net)
- Taken together, these data strongly implicate an unexplored role of Nrf2 in glioma resistance to Carmustine and raise the possible use of Nrf2 inhibitors as adjunct to Carmustine for the treatment of malignant glioma. (biomedcentral.com)
- These factors include price and availability of raw materials used in the carmustine manufacturing, demand from the end-use industries, import-export trends and others. (datavagyanik.com)
- Carmustine alkylates and cross-links DNA strands, inhibiting cell proliferation. (medscape.com)
- There are several factors that will contribute to the price trend of carmustine in the future. (datavagyanik.com)
- This carmustine manufacturing project report provides a microscopic view of this industry from manufacturing perspective. (datavagyanik.com)
- what is the total project cost for setting-up/starting carmustine manufacturing business? (datavagyanik.com)
- What is the working capital requirement for carmustine manufacturing project? (datavagyanik.com)
- Carmustine is in a class of medications called alkylating agents. (medlineplus.gov)
- Carmustine can cause a severe decrease in the number of blood cells in your bone marrow. (medlineplus.gov)
- Carmustine may increase the risk that you will develop other cancers. (medlineplus.gov)
- Your doctor will order certain tests to check your body's response to carmustine. (medlineplus.gov)
- The amount of Consuim (Carmustine) that you will recieve depends on many factors, including your height and weight, your general health or other health problems, and the type of cancer or condition being treated. (millionpharma.net)
- If you become pregnant while receiving carmustine, call your doctor. (medlineplus.gov)